company background image
REGN

Regeneron PharmaceuticalsNasdaqGS:REGN Stock Report

Last Price

US$621.40

Market Cap

US$65.0b

7D

1.0%

1Y

15.5%

Updated

23 Jan, 2022

Data

Company Financials +
REGN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance6/6
Financial Health6/6
Dividends0/6

REGN Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.

Regeneron Pharmaceuticals Competitors

AbbVie

NYSE:ABBV

US$233.3b

Amgen

NasdaqGS:AMGN

US$128.3b

Gilead Sciences

NasdaqGS:GILD

US$85.9b

Biogen

NasdaqGS:BIIB

US$32.4b

Price History & Performance

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share PriceUS$621.40
52 Week HighUS$686.62
52 Week LowUS$441.00
Beta0.17
1 Month Change-0.64%
3 Month Change7.84%
1 Year Change15.55%
3 Year Change48.56%
5 Year Change79.34%
Change since IPO2,841.54%

Recent News & Updates

Jan 19
Do Regeneron Pharmaceuticals's (NASDAQ:REGN) Earnings Warrant Your Attention?

Do Regeneron Pharmaceuticals's (NASDAQ:REGN) Earnings Warrant Your Attention?

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Jan 04
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Dec 24

Regeneron: Still Room To Grow

Regeneron easily beat the revenue and EPS expectation for 3Q 2021. Rapid revenue growth will continue into the foreseeable future, thanks to strong EYLEA, Dupixent, and Covid-treatment performance. Their balance sheet keeps getting stronger ($5.8 B, cash & short-term investments), and operating cash flow ($5.9 B, TTM) is rising. I expect 30-50% upside in the long run.

Dec 05
An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 41% Undervalued

An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 41% Undervalued

Does the December share price for Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) reflect what it's really worth...

Shareholder Returns

REGNUS BiotechsUS Market
7D1.0%-7.4%-6.1%
1Y15.5%-21.7%4.2%

Return vs Industry: REGN exceeded the US Biotechs industry which returned -22% over the past year.

Return vs Market: REGN exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement4.2%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: REGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: REGN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19889,766Leonard Schleiferhttps://www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN fundamental statistics
Market CapUS$64.97b
Earnings (TTM)US$7.00b
Revenue (TTM)US$13.36b

9.3x

P/E Ratio

4.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
REGN income statement (TTM)
RevenueUS$13.36b
Cost of RevenueUS$4.68b
Gross ProfitUS$8.68b
ExpensesUS$1.69b
EarningsUS$7.00b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 04, 2022

Earnings per share (EPS)66.91
Gross Margin65.00%
Net Profit Margin52.38%
Debt/Equity Ratio11.5%

How did REGN perform over the long term?

See historical performance and comparison

Valuation

Is Regeneron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

49.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: REGN ($621.4) is trading below our estimate of fair value ($1225.07)

Significantly Below Fair Value: REGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: REGN is good value based on its PE Ratio (9.3x) compared to the US Biotechs industry average (23.1x).

PE vs Market: REGN is good value based on its PE Ratio (9.3x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: REGN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: REGN is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (1.9x).


Future Growth

How is Regeneron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

-7.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's earnings are forecast to decline over the next 3 years (-7.3% per year).

Earnings vs Market: REGN's earnings are forecast to decline over the next 3 years (-7.3% per year).

High Growth Earnings: REGN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: REGN's revenue is expected to decline over the next 3 years (-2.9% per year).

High Growth Revenue: REGN's revenue is forecast to decline over the next 3 years (-2.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be high in 3 years time (21.7%)


Past Performance

How has Regeneron Pharmaceuticals performed over the past 5 years?

37.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REGN has high quality earnings.

Growing Profit Margin: REGN's current net profit margins (52.4%) are higher than last year (39.8%).


Past Earnings Growth Analysis

Earnings Trend: REGN's earnings have grown significantly by 37.3% per year over the past 5 years.

Accelerating Growth: REGN's earnings growth over the past year (121.7%) exceeds its 5-year average (37.3% per year).

Earnings vs Industry: REGN earnings growth over the past year (121.7%) exceeded the Biotechs industry 11%.


Return on Equity

High ROE: REGN's Return on Equity (40.5%) is considered outstanding.


Financial Health

How is Regeneron Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: REGN's short term assets ($13.8B) exceed its short term liabilities ($3.7B).

Long Term Liabilities: REGN's short term assets ($13.8B) exceed its long term liabilities ($2.7B).


Debt to Equity History and Analysis

Debt Level: REGN has more cash than its total debt.

Reducing Debt: REGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: REGN's debt is well covered by operating cash flow (300.1%).

Interest Coverage: REGN's interest payments on its debt are well covered by EBIT (124x coverage).


Balance Sheet


Dividend

What is Regeneron Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Leonard Schleifer (68 yo)

34yrs

Tenure

US$135,350,121

Compensation

Dr. Leonard S. Schleifer, M.D., Ph D., founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988. Dr. Schleifer served as the Chairman of Regeneron P...


CEO Compensation Analysis

Compensation vs Market: Leonard's total compensation ($USD135.35M) is above average for companies of similar size in the US market ($USD11.47M).

Compensation vs Earnings: Leonard's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: REGN's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: REGN's board of directors are seasoned and experienced ( 20 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: REGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Regeneron Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Regeneron Pharmaceuticals, Inc.
  • Ticker: REGN
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$64.971b
  • Shares outstanding: 104.56m
  • Website: https://www.regeneron.com

Number of Employees


Location

  • Regeneron Pharmaceuticals, Inc.
  • 777 Old Saw Mill River Road
  • Tarrytown
  • New York
  • 10591-6707
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:21
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.